Lilly, Aktis sign radiopharma pact | C&EN Global Enterprise

May 27, 2024 · Eli Lilly and Company has tapped Boston biotechnology firm Aktis Oncology to make new radiopharmaceuticals for solid tumors. Lilly will pay Aktis $60 million up front and up …

CouponFollow Extension

$60
OFF

Lilly, Aktis Sign Radiopharma Pact | C&EN Global Enterprise

4 weeks from now

May 27, 2024 · Eli Lilly and Company has tapped Boston biotechnology firm Aktis Oncology to make new radiopharmaceuticals for solid tumors. Lilly will pay Aktis $60 million up front and up …

acs.org

$60
OFF

Lilly, Aktis Sign Radiopharmaceuticals Pact - Chemical

4 weeks from now

May 23, 2024 · Eli Lilly and Company has tapped Boston biotechnology firm Aktis Oncology to make new radiopharmaceuticals for solid tumors. Lilly will pay Aktis $60 million up front and up …

acs.org

$140
OFF

Lilly Signs Another Radiopharma Pact | C&EN Global Enterprise

4 weeks from now

Jul 15, 2024 · Eli Lilly and Company is backing another radiopharmaceutical developer, this time paying San Diego–based Radionetics $140 million up front to make drugs that target a family …

acs.org

$1
OFF

Lilly Partners With Aktis, Deepening Radiopharma Investment

4 weeks from now

May 21, 2024 · Per terms announced Tuesday, Aktis could receive as much as $1.1 billion more from Lilly if certain milestones are met. Lilly is also making an equity investment in Aktis. In …

biopharmadive.com

$84
OFF

Lilly Collaborates With Aktis To Strengthen Radiopharma Portfolio

4 weeks from now

May 21, 2024 · Aktis previously received backing from pharma giants Merck & Co, Novartis, and Bristol Myers Squibb (BMS) when it closed a $84m Series A extension round in August 2022. …

pharmaceutical-technology.com

$60
OFF

Eli Lilly Pays $60M Upfront For Radiopharmaceutical Pact With Aktis

4 weeks from now

Under the terms of the agreement, Aktis will receive a $60M upfront cash payment for the collaboration in addition to an equity investment in Aktis by Lilly. In addition, Aktis will be …

tipranks.com

$1
OFF

Lilly Takes Another Dip Into Radiopharma, Via Deal With Aktis …

4 weeks from now

May 21, 2024 · Last year Lilly punted $1.4 billion on the acquisition of Point Biopharma, gaining rights to PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand therapy …

thepharmaletter.com

$140
OFF

Lilly Signs $140M Radiopharma Partnership With Radionectics

4 weeks from now

Jul 1, 2024 · Eli Lilly pays Aktis $60M upfront to further dial into radiopharma signal The biotech hauled in a $52.5 million series A at the start of this year, bringing the total the company had …

fiercebiotech.com

$140
OFF

Lilly Builds In Radiopharma With $140m Radionetics Deal

4 weeks from now

4 days ago · Meanwhile, in May, Lilly paid $60 million upfront to use Aktis Oncology's technology to generate radiopharma candidates for solid tumours in a deal that could be worth up to $1.1 …

pharmaphorum.com

$1
OFF

Eli Lilly Inks Another Radiopharma Deal, Gaining Option To Buy Startup

4 weeks from now

Jul 1, 2024 · Eli Lilly is expanding further into radiopharmaceuticals, inking a deal with Radionetics Oncology that gives it an option to later acquire the San Diego biotechnology company for $1 …

biopharmadive.com

$175
OFF

Radiopharma Start-up Aktis Raises $175 Million | C&EN Global …

4 weeks from now

Oct 14, 2024 · Aktis Oncology, a radiopharmaceutical firm that launched in 2021, has raised $175 million in a series B financing round co-led by RA Capital Management, RTW Investments, …

acs.org

$140
OFF

Lilly Enters $140 Million Radiopharmaceutical Pact

4 weeks from now

Jul 11, 2024 · Eli Lilly and Company is backing another radiopharmaceutical developer, this time paying San Diego–based Radionetics $140 million up front to make drugs that target a family …

acs.org

FAQs about Lilly, Aktis sign radiopharma pact | C&EN Global Enterprise Coupon?

Will Lilly acquire aktis pharmaceuticals?

Under the terms of the agreement, Lilly will gain worldwide rights to develop targets for radiopharmaceuticals discovered by Aktis. However, the deal does not include Aktis’ current pipeline, which consists of seven programmes. ...

What will Eli Lilly do with a global radiopharmaceutical exchange?

As an exchange, Eli Lilly will acquire worldwide rights to develop and commercialize radiopharmaceutical therapeutic and diagnostic products based on oncology targets selected by Lilly. ...

Will Eli Lilly buy radionetics oncology?

Save the Date for LEAP HR: Life Sciences Europe! 18th-20th February, 2025, London, UK. Eli Lilly pays $140m for a stake in radiopharma drugs developed by Radionetics Oncology and takes an option on buying the biotech outright for $1bn. ...

Will Lilly buy radionetics?

Radionetics will continue to build its radiopharmaceutical drug pipeline through an “exercise period,” after which Lilly can choose whether to acquire the company. Radionetics is developing small molecule radiopharmaceuticals that can target G protein-coupled receptors, a ubiquitous family of proteins that present many attractive disease targets. ...